Nicox Sa · EURONEXT:ALCOX
Nicox Sa — Investor Presentation (September 2026)
28 slides from Nicox Sa's investor presentation, Sep 11, 2026
Slide 1: Nicox Corporate Presentation
Euronext Growth Paris (Ticker symbol: ALCOX) Nicox Corporate Presentation An international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health September 11, 2026
Slide 2: Forward-Looking Statements
Forward - Looking Statements This document has been prepared by Nicox SA and may not be reproduced or distributed, in whole or in part. The information contained in this document has not been independently verified and no representation, warranty or undertaking, expressed or implied, is made as to,
Slide 3: Latest news
Latest news 2 New Drug Application s submitted for NCX 470, in the United States and in China NICOX visible science Both partners have commercial operations in their respective territories and are therefore well-placed to launch NCX 470 when approved. For details see: Kowa Pharmaceuticals America an
Slide 4: U.S. Partner, Kowa, Preparing for Commercial Launch
NCX 470 U.S. Partner, Kowa, Preparing for Commercial Launch 1,2 Subject to NDA approval, U.S. launch planned for H2 2027 “The FDA’s acceptance of the NDA for K-911 marks an important milestone as we work toward bringing a potential new treatment option to NICOX visible science people living with ope
Slide 5: Nicox at a glance
Nicox at a glance Revenue - generating ophthalmology biotech developing sight - saving therapies Late-stage program Commercial-stage Global reach NICOX visible science in glaucoma with Significant market assets and R&D with top-tier opportunity: 80 mn NDAs1 accepted for collaborations worldwide glau
Slide 6: Corporate highlights
Corporate highlights NCX 470 : A Proven Strategic Large Potential Two NDAs Track Transaction Market for submitted in Record Capability NCX 470 major markets NICOX visible science Two commercialized Corporate team NDAs submitted in ~$7 bn worldwide products in the U.S., with significant U.S. (PDUFA d
Slide 7: Nicox Portfolio: Track Record of Ophthalmology Innovation
Nicox Portfolio: Track Record of Ophthalmology Innovation Near Term Value through NCX 470, a Derisked Product Candidate with Global Potential Preclinical Clinical NDA Marketed Partner VYZULTA® Glaucoma and Ocular Worldwide1 NICOX visible science Latanoprostene Bunod Hypertension Ophthalmic Sol. 0.02
Slide 8: Milestones
NCX 470 Milestones Significant NCX 470 future news NDA submission in the U.S. – Achieved June 2026 NDA submission in China – Achieved August 2026 NICOX visible science Japan clinical trials results – Trials ongoing NDA approval in the U.S. – PDUFA1 date 30 April 2027 Launch in the U.S. – H2 2027, su
Slide 9: NCX 470 highlights and market
NCX 470 highlights and market • Novel, fast and dual acting molecule demonstrating best-in-class IOP lowering efficacy of up to 10mmHg from baseline • U.S. and Chinese NDAs filed based on NICOX visible science positive pivotal Phase 3 topline results from the Mont Blanc1 and Denali 2 NCX 470 • Precl
Slide 10: Glaucoma: a Significant Worldwide Ophthalmic Disease
Glaucoma: a Significant Worldwide Ophthalmic Disease Elevated IOP 1 Contributes to Irreversible Optic Nerve Damage, Leading to Progressive Vision Loss NICOX visible science As published in the landmark EMGT study “…each mmHg of decreased IOP was related to an approximately 10% lowering [of risk of v
Slide 11: Lowers IOP via a Validated Dual Mechanism Pathway
NCX 470 Lowers IOP via a Validated 1 Dual Mechanism Pathway Clinically Validated in Two Phase 3 trials, and Dual Mechanism of Action Proven in a Phase 3b Two Pathways for Aqueous Humor 1 Primary or conventional outflow normally Stimulated by nitric oxide (NO) Outflow1,2 accounts for ~60% to NICOX vi
Slide 12: Unmet Medical Needs for Glaucoma Treatment
Unmet Medical Needs for Glaucoma Treatment 40% of patients Many patients Tolerability issues Despite having well do not achieve require >1 with some established first-line therapies, their target IOP medication medications lead to NICOX visible science including the standard-of-care, on existing whi
Slide 13: NDA submitted in U.S and in China
NCX 470 NDA submitted in U.S and in China August 2025 Summer 2026 H2 2027 Topline Results of NDA submissions Potential launch NICOX visible science Denali Phase 3 in the United in the United Clinical Trial States and China States1 • U.S. NDA submitted in June 2026 with a PDUFA date of 30 April 2027
Slide 14: Clinical Program
NCX 470 Clinical Program Primary objective of non - inferiority met, supporting NDA submission Image for illustrative purposes only N = 691 56 clinical sites in the U.S. & one site in China Phase 3 studies were Mont Blanc1 NICOX visible science Adaptive design selected the 0.1% designed to demonstra
Slide 15: Phase 3 Trial Design – Efficacy Assessment Period
NCX 470 Phase 3 Trial Design 1 – Efficacy Assessment Period NCX 470 vs. standard of care, Latanoprost Randomized, controlled, double-masked, parallel design trial. Patients with open angle glaucoma or ocular hypertension were randomized 1:1 to once-daily treatment with NCX 470 0.1% or latanoprost 0.
Slide 16: Rapid and Sustained IOP-Lowering Effects
Rapid and Sustained IOP - Lowering Effects Demonstrated in two Phase 3 studies Mont Blanc1 Denali2 NICOX visible science • NCX 470 0.1%: N = 328 Latanoprost 0.005%: N = 333 • NCX 470 0.1%: N = 348 Latanoprost 0.005%: N = 348 • IOP-Lowering from Baseline was 8.0 to 9.7 mmHg for • IOP-Lowering from Ba
Slide 17: Phase 3 Results Confirm Robust Efficacy
NCX 470 Phase 3 Results Confirm Robust Efficacy 1,2,3 Based on Topline Results from both Pivotal Trials 4 • IOP-lowering effect from baseline was 7.9 - 10.0 mmHg for NCX 470 vs. 7.1 to 9.8 mmHg for latanoprost in the trials. NICOX visible science • Statistical non-inferiority was met vs. latanoprost
Slide 18: Well Tolerated in Both Phase 3 Trials
NCX 470 Well Tolerated in Both Phase 3 Trials 1,2,3 No ocular or non ocular serious adverse events related to NCX 470 Mont Blanc Denali NCX 470 Latanoprost NCX 470 Latanoprost NICOX visible science Ocular Hyperemia Conjunctival Hyperemia Hyperemia (most common adverse effect) 11.9% 3.3% 22.0% 9.2% L
Slide 19: Post hoc Data Further Differentiates vs. Standard of Care
NCX 470 Post hoc Data Further Differentiates vs. Standard of Care All Comparisons Are Based on NCX 470 0.1% and Latanoprost 0.005% in Mont Blanc 1,2 • Statistically significantly greater percentage of patients achieve ≤ 18mmHg IOP on NCX 470 compared to latanoprost NICOX visible science • Mean perce
Slide 20: Publications and Presentations
NCX 470 – Publications and Presentations A Randomized Trial Comparing NCX 470 0.1%, a Nitric Oxide-Donating Bimatoprost, and NICOX visible science Latanoprost 0.005% for Open-Angle Glaucoma or Ocular Hypertension: The DENALI Trial Authors: S. Asrani, MD, Professor of Ophthalmology, and D. Hubatsch,
Slide 21: Global Licensing of NCX 470
Global L icensing of NCX 470 United States Japan Partnership Partnership with with Kowa Kowa PDUFA date Phase 3 trials 30 April 2027 ongoing NICOX visible science China, Korea and Southeast Asia Partnership with Ocumension NDA in China accepted for review on 10 September 2026 Rest of World Partnersh
Slide 22: Kowa – NCX 470 Partnership
Kowa – NCX 470 Partnership Two value - creating deals • Founded in Japan in 1894; Active worldwide February 2024 July 2025 in multiple domains including life sciences 1 • ~8000 employees with an annual group revenue United States NICOX visible science and all territories outside of $4.9 billion Japa
Slide 23: Ocumension - NCX 470 Partnership
Ocumension - NCX 470 Partnership Shareholder of Nicox and Commercial partner for ZERVIATE China • Chinese company created in 2018 and dedicated December 2018 to ophthalmology1 • Listed on the Hong Kong stock exchange China, NICOX visible science since 2020 - ~$800 million market cap Korea, Southeast
Slide 24: Commercial Products and Partnerships
Commercial Products and Partnerships NICOX visible science Same mechanism 5% to 9% royalties 8% to 15% royalties of action as on annual net sales on annual net NCX 470 in China1 sales in the U.S. 2 Launched in over 15 First Commercial Launched3 in countries including sale in China the U.S. the U.S.4
Slide 25: Glaukos - Research Collaboration on NCX 1728
Glaukos - Research Collaboration on NCX 1728 NO-donating PDE5 inhibitor Combining NO-mediated MOA is enhanced NO-Release and prolonged by concomitant with PDE5 phosphodiesterase-5 (PDE5) Inhibition inhibition within the same molecule NICOX visible science NO is an important mediator in both IOP Pote
Slide 26: Financial information
Financial information Nicox is listed on Euronext Growth Paris (Ticker symbol: ALCOX) NICOX visible science Cash runway1 Analyst coverage Financial Information (links): 12+ months Yi Chen Annual Report 2025 HC Wainwright Financial Results 2025 Stock Information 26 1. As at the date of this presentat
Slide 27: Corporate highlights
Corporate highlights NCX 470 : A Proven Strategic Large Potential Two NDAs Track Transaction Market for submitted in Record Capability NCX 470 major markets NICOX visible science Two commercialized Corporate team NDAs submitted in ~$7 bn worldwide products in the U.S., with significant U.S. (PDUFA d
Slide 28: Nicox S.A.
Euronext Growth Paris (Ticker symbol: ALCOX) Nicox S.A. Sundesk Sophia Antipolis Emerald Square Bâtiment C rue Evariste Galois 06410 Biot, France T: +33 (0)4 97 24 53 00 communications@nicox.com www.nicox.com